

ASX & Media Release

Patrys Granted Key Patent for Lead Product – PAT-LM1

- **Issued New Zealand patent for lead product PAT-LM1 offers protection through to year 2029**
- **Patent covers use of PAT-LM1 or binding fragments of PAT-LM1 for the treatment or prevention of metastasis**

Melbourne, Australia; 6 June, 2013: Patrys Limited (**ASX: PAB**), a clinical stage biopharmaceutical company is pleased to advise that it has been granted a New Zealand patent for lead anti-cancer product PAT-LM1.

The New Zealand Patent Office has issued a certificate of grant on a key patent in the PAT-LM1 family, PCT/IB2009/007082 entitled “LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same”. This is the second jurisdiction in which the PAT-LM1 patent has been granted.

“New Zealand is a major market in the Australasian region, and it is very pleasing to add this patent to Patrys’ already extensive portfolio, which includes patents in other key jurisdictions”, said Dr. Marie Roskrow, Patrys’ Chief Executive Officer.

The patent, which is owned by Patrys, claims the use of the antibody PAT-LM1 that binds to its target Nmt55/NONO for the treatment or prevention of metastasis.

PAT-LM1 is currently under preclinical development.

-Ends-

For further information, please contact:

Patrys Limited:
Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
rwilson@buchanwe.com.au

Patrys Media:
Shevaun Cooper
Buchan Consulting
P: +61 3 9866 4722
scooper@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com